An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer

Inclusion Criteria: * Pathologically confirmed Non-small cell lung cancer * Patients with extracranial measurable lesions * Patients with NSCLC failed for standard treatments * Eastern Cooperative Oncology Group performance status score: 0\~2 and life expectancy of more than 3 months * Major organs functioning properly * Compliance is good and agreed to cooperate with the survival of follow-up * Informed consent Exclusion Criteria: * Contraindications for investigational agents * Patients with clinical symptoms of brain metastases or meningeal metastasis * Tumor invade big vessels or close to big vessels * Uncontrolled hypertension * Abnormal coagulation (INR\>1.5 or Prothrombin Time\>ULN+4, or Activated Partial Thromboplastin Time\>1.5 ULN), bleeding tendency or receiving coagulation therapy * Hemoptysis, more than 2.5ml daily * Thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous thrombosis. * Myocardial ischemia or infarction more than stage II, cardiac insufficiency. * Received big surgery, had bone fracture or ulcer in 4 weeks. * Urine protein≥++, or urine protein in 24 hours≥1.0g